Supplier qualification
Identity, business documentation, specifications, and change controls are reviewed before a source is approved.
QUALITY FRAMEWORK
Evidence over adjectives.
Our operating model is designed to make each material traceable through a documented chain of receipt, review, release, inventory, and shipment.
Controlled receipt
Incoming materials receive an internal lot record and remain segregated from released inventory.
Documentation review
Specifications and supporting analytical records are evaluated for the represented material and lot.
Release decision
A completed release review requires an authorized disposition. Items explicitly marked Documentation pending may be offered with checkout acknowledgment; that does not constitute an approved COA or a completed release review.
Inventory traceability
Available quantity, storage, allocation, and order linkage are maintained at the lot level.
Post-shipment records
Tracking, customer communication, exceptions, and approved claims remain linked to the order record.
CERTIFICATES OF ANALYSIS
Specific to the released lot.
A document is useful only when it maps cleanly to the material in hand. Public records are designed to show the lot identifier, represented material, relevant specification summary, document date, and source certificate where approved.
Search COAsCOA review principles
- No generic certificate presented as lot-specific
- No unsupported “pharmaceutical grade” or approval claims
- No purity statement without matching documentation
- No released status while required review is incomplete
- Corrections and replacements remain auditable
IMPORTANT DISTINCTION
Documentation is not an authorization for human use.
Analytical results describe tested attributes under the stated method and conditions. They do not establish clinical safety, efficacy, sterility, suitability for administration, or regulatory approval.